期刊文献+

乳腺癌中AKT激活与耐药蛋白表达相关性 被引量:4

Correlation of AKT activation with drug resistance protein expression in breast cancer
下载PDF
导出
摘要 目的明确乳腺癌中Akt的过度表达与P-gp、GST-π、TopoⅡ三种耐药蛋白的相关性。方法采用免疫组织化学方法检测260例乳腺癌中Akt和P-gp、TopoⅡ、GST-π的表达情况。结果乳腺癌中Akt、GST-π和TopoⅡ的表达与肿瘤大小相关,随着肿瘤体积增大,AKT、GST-π和TopoⅡ的阳性表达率增高;Akt和P-gp在伴有淋巴结转移的病例中高表达,且随着淋巴结的数目增多Akt表达越来越高;Akt、P-gp和GST-π的阳性表达患者预后差;Akt与P-gp、GST-π、Topo-Ⅱ阳性表达之间均呈显著相关性。结论信号转导途径中Akt的激活与P-gp、GST-π、TopoⅡ三种耐药蛋白有相关性,AKT有可能在乳腺癌多药耐药的发生机制中起到一定的作用。 Objective To explain whether over-expression of the Akt gene is correlated to the expressions of P-gp, GST-π and TopoⅡ in breast cancer. Methods SP immunohistochemical method was used to examine the expressions of Akt, P gp, GST-π and Topo Ⅱ in 260 samples of primary breast cancer. Results Akt, GST- and Topo π expressions in breast cancer were positively associated with tumor size. High expression of Akt and P-gp were seen in the cases with lymph node metastasis, and the expression of Akt became higher and higher with the increase in the number of lymph nodes. The positive expressions of Akt, P-gp and GST-= indicated poor prognosis. There were significant correlations between Akt and positive expressions of P-gp, GST-πand Topo Ⅱ. Conclusion Activation of Akt in the signal transduction pathway is correlated with resistance proteins P-gp, GST-π, and Topo Ⅱ. AKT may play a certain role in the mechanism of multidrug resistance in breast cancer.
出处 《中国组织化学与细胞化学杂志》 CAS CSCD 2012年第4期401-405,共5页 Chinese Journal of Histochemistry and Cytochemistry
关键词 AKT P-GP GST-Π TopoⅡ 乳腺癌 Akt P gp GST-π TopoⅡ Breast Cancer
  • 相关文献

参考文献13

  • 1Hitoshi T, Chinami S, Shoichiro T, et al. Aprospective study of the significance of the gene and chromosome alteration as prognostic indicators of breast cancer patients with lymphnode metastases. Breast Cancer Res Treat,1998,48(1) :21-32.
  • 2Rolff J, Dorn C, Merk J, et al. Response of Patient-Derived Non-Small Cell Lung Cancer Xenografls to Classical and Targeted Therapies Is Not Related to Multidrug Resistance Markers. J Oncol,2009, 814140.
  • 3Shi H, Lu D, Shu Y, et al. Expression of multidrug resistance-related proteins p-glycoprotein, glutathione-stransferases, topoisomerase lI and lung resistance protein in primary gastric cardiac adenocarcinoma. Hepatogastroenterology,2008,55(86 87):1530-1536.
  • 4de Figueiredo-Pontes LL, Pintao MC, Oliveira LC, et al. Determination of P-glycoprotein, MDR related protein 1, breast cancer resistance protein, and lung-resistance protein expression in leukemic stem cells of a cute myeloid leukemia. Cytometry B Clin Cytom, 2008, 74(3): 163-168.
  • 5Gangemi R, Paleari L, Orengo AM, et al. Cancer stem cells: a new paradigm for understanding tumor growth and progression and drug resistance. Curr Med Chem, 2009,16(14) :1688-1703.
  • 6Jakobson I, Warholm M, Mannervik B. The binding of substrates and a product of the enzymatic reaction to glutathione S-transferase A. J Biol Chem. 1979, 254 (15) : 7085-7089.
  • 7Kim SU, Lee KM, Park SK, et al. Genetic polymorphism of glutathione S-transferase P1 and breast cancer risk. J Biochem Mol Biol. 2004, 37(5): 582-585.
  • 8Kantidze OL, Razin SV. Chemotherapy-related secondary leukemias.. A role for DNA repair by error-prone non-homologous end joining in topoisomerase Ⅱ Induced chromosomal rearrangements. Gene. 2007, 391 (1-2) : 76-79.
  • 9Perry MC. The chemotherapy source Book. 3th ed. Philadelphia: Lippincott Williams and Wilkins, 2002:278-289.
  • 10Pusztai L. Current 8tatus of prognostic profiling in breast cancer. Oncologist, 2008, 13 : 350-360.

同被引文献64

引证文献4

二级引证文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部